MacroGenics, Inc. Announces Proposed Public Offering Of Common Stock

ROCKVILLE, Md., Feb. 10, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. The offering is expected to consist of 1,500,000 shares to be offered by MacroGenics and 1,000,000 shares to be offered by existing stockholders. MacroGenics will not receive any proceeds from the sale of shares by the selling stockholders. In addition, MacroGenics intends to grant the underwriters a 30-day option to purchase up to 375,000 shares of common stock.

Help employers find you! Check out all the jobs and post your resume.